Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8269390 | 0.96 | PARP1 (0.73) | PARP1PARP3 | |
| SCHEMBL78374 | 0.84 | PARP1 (0.59) | PARP1 | |
| SCHEMBL1689488 | 0.83 | PARP1 (1.00) | PARP1 | |
| SCHEMBL30415984 | 0.83 | PARP1 (1.00) | PARP1 | |
| SCHEMBL78182 | 0.82 | PARP1 (0.58) | PARP1PARP3 | |
| SCHEMBL13495551 | 0.82 | PARP1 (0.57) | PARP1 | |
| SCHEMBL78096 | 0.82 | PARP1 (0.58) | PARP1PARP3 | |
| SCHEMBL3350841 | 0.82 | PARP1 (0.73) | PARP1PARP3 | |
| SCHEMBL8269392 | 0.82 | PARP1 (0.61) | PARP1 | |
| SCHEMBL76707 | 0.81 | PARP1 (0.62) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| EP-1791827-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2007-06-06 | — | — | EP | disclosed |
| US-20060063767-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LTD (GB) | 2006-03-23 | — | — | US | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | PARP1, PARP2, PARP11 | PARP1 1/4885PARP3 4/4885 |
| US-20060063767-A1 | Phthalazinone derivatives | PARP1, PARP2, NR0B1 | PARP1 1/4885PARP3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.